Coya Therapeutics, Inc. COYA
Coya Therapeutics, Inc. (Nasdaq: COYA) is a CNS/neurology/psychiatry drug developer. Its lead program, COYA 302 (low-dose IL-2 + CTLA4-Ig), is in Phase 2 for Amyotrophic lateral sclerosis (ALS). Its next catalyst on record is COYA 302: The planned initiation of the Phase 2 clinical trial evaluating COYA 302 in frontotemporal dementia, previously anticipated in the second half of 2026, is now expected in 2027. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: COYA 302 — The planned initiation of the Phase 2 clinical trial evaluating COYA 302 in frontotemporal dementia, previously anticipated in the second half of 2026, is now expected in 2027. (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| COYA 302 - ALSTARS | ALS | protein/peptide | Phase 2 |
| COYA 302 - FTD | Frontotemporal dementia | protein/peptide | Phase 1 |
| COYA 201 / COYA 206 (Treg-derived exosomes) | — | biologic-other | Pre-clinical |
| COYA 303 | — | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 14, 2026started Open-label extension of Phase 2/3 ALSTARS Trial evaluating COYA 302 in ALS expected to begin in November 2026.
The Company expects the OLE to begin in November 2026 as the first cohort completes the 48-week treatment period.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.